Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Consensus Rating of “Moderate Buy” from Brokerages

Genmab A/S Sponsored ADR (NASDAQ:GMAB) has earned an average recommendation of “Moderate Buy” from the thirteen research firms that are currently covering the stock, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation, nine have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $40.83.

A number of research analysts recently issued reports on GMAB shares. Weiss Ratings raised Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, September 1st. New Street Research set a $43.00 price objective on shares of Genmab A/S in a research report on Wednesday, July 22nd. Guggenheim boosted their target price on shares of Genmab A/S from $45.00 to $54.00 and gave the stock a “buy” rating in a research note on Monday. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Genmab A/S in a research report on Monday, September 14th. Finally, TD Cowen raised shares of Genmab A/S from a “hold” rating to a “buy” rating and increased their price target for the company from $32.00 to $43.00 in a research note on Wednesday, July 22nd.

Genmab A/S Stock Up 10.7%

Shares of GMAB opened at $38.48 on Thursday. The company has a market capitalization of $24.01 billion, a P/E ratio of 30.30, a PEG ratio of 1.89 and a beta of 0.81. Genmab A/S has a one year low of $23.62 and a one year high of $40.17. The business’s 50 day simple moving average is $32.96 and its 200-day simple moving average is $29.06. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.46 and a quick ratio of 2.44.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.17. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.12 billion. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%. As a group, sell-side analysts predict that Genmab A/S will post 1.21 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of GMAB. Arrowstreet Capital Limited Partnership boosted its stake in Genmab A/S by 36.6% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company’s stock worth $153,324,000 after acquiring an additional 1,334,919 shares during the last quarter. First Trust Advisors LP grew its holdings in Genmab A/S by 84.3% during the first quarter. First Trust Advisors LP now owns 2,461,342 shares of the company’s stock valued at $66,038,000 after purchasing an additional 1,126,069 shares during the period. Renaissance Technologies LLC increased its stake in Genmab A/S by 26.4% in the first quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company’s stock valued at $118,442,000 after purchasing an additional 921,700 shares in the last quarter. Cibc World Market Inc. raised its holdings in Genmab A/S by 31.2% in the fourth quarter. Cibc World Market Inc. now owns 367,282 shares of the company’s stock worth $11,312,000 after purchasing an additional 87,350 shares during the period. Finally, SummitTX Capital L.P. acquired a new stake in Genmab A/S in the first quarter worth $2,263,000. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including its DuoBody and HexaBody platforms, to create therapies designed to engage the immune system, target disease-related proteins and improve treatment outcomes.

Genmab’s portfolio includes products developed through partnerships as well as internally discovered candidates.